Triastek has successfully concluded a pre-Series C funding round of $20.4 million to expedite the commercialization of their 3D printing pharmaceutical technology and products.


Title: Transforming Drug Development: Triastek’s Innovative Solutions


The pharmaceutical industry is constantly evolving, with new technologies and innovations revolutionizing drug development and manufacturing. Triastek, a global leader in 3D printing pharmaceuticals, has emerged as a pioneer in this field. With its ground-breaking Melt Extrusion Deposition (MED®) 3D printing process and digital formulation development methods, Triastek is transforming the way medications are delivered, developed, and produced. In a recent financing round, the company raised USD 20.4 million, marking a significant milestone in its journey towards advancing innovative solutions for pharmaceutical needs.

Impressive Achievements:

Since its inception in 2015, Triastek has achieved remarkable milestones, solidifying its position as a global leader in 3D printing pharmaceuticals. The company holds the highest number of patents in the realm of pharmaceutical 3D printing technology, accounting for over 20% of patent applications worldwide. Triastek also boasts the largest number of 3D-printed products, with several gaining clearance from regulatory bodies such as the US FDA and the National Medical Products Administration (NMPA). Furthermore, the company operates the highest production capacity in 3D-printed drug manufacturing, with a state-of-the-art continuous production line that meets Good Manufacturing Practice (GMP) standards. Triastek’s exceptional achievements have earned it recognition as the only Chinese pharmaceutical company selected for the US FDA’s Emerging Technology Program (ETP).

Influential Partnerships:

Triastek’s commitment to innovation and collaboration is evident in its strategic partnerships with prominent global pharmaceutical companies. Collaborations with industry giants such as Eli Lilly, Merck KGaA, Boehringer Ingelheim, Siemens, and Sperogenix have propelled the development and application of 3D printing technology in pharmaceuticals. These partnerships focus not only on novel product development but also on advanced technical solutions, paving the way for groundbreaking advancements in the field.

Vision for the Future:

Dr. Senping Cheng, Founder and CEO of Triastek, envisions a future where the MED process and platform are fully commercialized, driving digital product development and intelligent manufacturing. With the successful completion of the recent financing round, Triastek intends to expand its collaborations, achieve technical advancements, and become a benchmark enterprise in high-end formulations. This forward-thinking approach will contribute to the modernization of China’s pharmaceutical industry while delivering clinical benefits to patients worldwide.

Support and Recognition:

Triastek’s pioneering work has gained recognition and support from various stakeholders. Guoxin Investment, a leading participant in the recent financing round, acknowledges Triastek as a global leader and expresses excitement about the company’s potential for expansion and technical advancements. Goldmine Multi-family Office, another participant, highlights the value of supporting groundbreaking companies like Triastek to achieve high-quality inheritance and make meaningful contributions to society. Mr. Xiaodong Zheng, president of Shanghai Tofflon Science and Technology Co. Ltd., emphasizes the significance of Triastek’s emerging technology and its potential to aid China’s pharmaceutical modernization efforts. China Renaissance, the exclusive financial advisor for the financing round, also recognizes Triastek’s vast application potential and commits to supporting the company’s development journey.


Triastek’s innovative solutions and dedication to transforming drug development and manufacturing through 3D printing pharmaceuticals have placed the company at the forefront of the industry. With its MED process and platform, Triastek aims to revolutionize the pharmaceutical sector, unlocking the next generation of medicines for the benefit of patients worldwide. By fostering strategic partnerships and garnering support from investors and industry experts, Triastek is well-positioned to drive advancements in the digital product development and intelligent manufacturing space. As we look to the future, Triastek’s commitment to delivering innovative drug products and achieving clinical benefits remains steadfast.

Note: While the original blog post included specific quotes from individuals, they have been excluded in this version, as per the instruction to write differently while keeping the story and logic the same.

Title: Redefining the Future: Empowering the Global Healthcare Ecosystem


In an era where innovation reigns supreme, revolutionizing the pharmaceutical industry has become a necessity rather than a luxury. Our unwavering commitment to enhancing the quality of pharmaceuticals and transforming healthcare worldwide has positioned us as a pioneering force in the pursuit of becoming the world’s foremost intelligent pharmaceutical enterprise. Join us as we embark on a journey to reshape the future of healthcare, one breakthrough product at a time.

Unveiling Evolutionary Products:

At the heart of our mission lies a relentless drive to push the boundaries of scientific and technological advancements. As we strive to improve pharmaceutical quality, we introduce a range of revolutionary products that promise to transform patient care and revolutionize healthcare systems worldwide.

1. Intelligent Medication Delivery System: Imagine a future where precise and personalized drug dosages are administered seamlessly. Our pioneering medication delivery system utilizes cutting-edge artificial intelligence algorithms to optimize treatment plans based on individual patient characteristics, ensuring enhanced therapeutic outcomes while minimizing adverse effects.

2. Smart Pill: Say goodbye to medication compliance issues with our groundbreaking smart pill technology. By embedding microchips within pharmaceuticals, we enable real-time monitoring of medication adherence. This innovative solution not only improves patient compliance but also enables healthcare providers to track treatment progress more accurately.

3. Nanobots for Targeted Drug Delivery: Harnessing the power of nanotechnology, we introduce a breakthrough concept in drug delivery. Our minuscule yet incredibly intelligent nanobots navigate the human body, delivering medications directly to disease sites. This precision-based approach not only minimizes side effects associated with conventional treatments but also maximizes therapeutic efficacy.

Empowering the Healthcare Ecosystem:

True transformation necessitates collaboration and partnerships across the entire healthcare ecosystem. By fostering meaningful alliances with healthcare providers, research institutions, and technological innovators, we amplify our impact and accelerate advancements in the field of pharmaceuticals.

1. Research Collaborations: We actively engage with leading academic institutions and research organizations to drive fundamental scientific breakthroughs. By joining forces, we aim to unlock novel treatment options, develop innovative drug delivery systems, and bring cutting-edge therapies to patients faster.

2. Technological Integration: Recognizing that true transformation lies at the intersection of healthcare and technology, we collaborate with industry leaders to harness the power of artificial intelligence, machine learning, and data analytics. By leveraging these digital advancements, we enhance pharmaceutical quality, optimize treatment approaches, and improve patient outcomes.


As we march towards a future characterized by intelligent pharmaceuticals, we believe that our vision of becoming the world’s most influential intelligent pharmaceutical enterprise is within reach. Through groundbreaking products and collaborative partnerships, we are equipped to reshape the global healthcare landscape, revolutionizing patient care and empowering healthcare providers with unprecedented tools and solutions. Together, let us embrace this transformative journey and shape a future where healthcare is accessible, precise, and compassionate.

Original source


“Why did the 3D printer go to therapy? Because it had too many layers of unresolved issues!”

Like it? Share with your friends!


Meet the mastermind behind GCode-Guru, a 3D printing wizard whose filament collection rivals their sock drawer. Here to demystify 3D tech with a mix of expert advice, epic fails, and espresso-fueled rants. If you've ever wondered how to print your way out of a paper bag (or into a new coffee cup), you're in the right place. Dive into the world of 3D printing with us—where the only thing more abundant than our prints is our sarcasm.


Your email address will not be published. Required fields are marked *

Choose A Format
Personality quiz
Series of questions that intends to reveal something about the personality
Trivia quiz
Series of questions with right and wrong answers that intends to check knowledge
Voting to make decisions or determine opinions
Formatted Text with Embeds and Visuals
The Classic Internet Listicles
The Classic Internet Countdowns
Open List
Submit your own item and vote up for the best submission
Ranked List
Upvote or downvote to decide the best list item
Upload your own images to make custom memes
Youtube and Vimeo Embeds
Soundcloud or Mixcloud Embeds
Photo or GIF
GIF format